Limits...
Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.

Kurabayashi A, Inoue K, Fukuhara H, Karashima T, Fukata S, Kawada C, Shuin T, Furihata M - Cancer Sci. (2015)

Bottom Line: The antiangiogenetic effect by YM529 and/or IFN-α was analyzed using micro-vessel density and in situ mRNA hybridization.Neither YM529 nor IFN-α alone significantly inhibited the growth of established bone metastatic tumors.Their effects are mediated by osteoclast recruitment inhibition and inactivation by YM529 and antiangiogenesis by IFN-α.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Kochi Medical School, Nankoku, Japan.

Show MeSH

Related in: MedlinePlus

Micro-vessel density was significantly lower in tumors treated with IFN-α alone or in combination with YM529 than in control tumors (*P = 0.0275, **P = 0.0252) and in tumors of the single-agent YM 529-treatment group (***P = 0.0202, ****P = 0.0285).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4556400&req=5

fig07: Micro-vessel density was significantly lower in tumors treated with IFN-α alone or in combination with YM529 than in control tumors (*P = 0.0275, **P = 0.0252) and in tumors of the single-agent YM 529-treatment group (***P = 0.0202, ****P = 0.0285).

Mentions: mRNA expression of bFGF, VEGF, IL-8, MMP-9, MMP-2, E-cadherin and EGFR was analyzed by ISH (Table3, Fig.6), and MVD was determined by IHC (Fig.7). In RBM1-IT4 cells growing in the tibia of athymic nude mice, bFGF mRNA expression within the tumors of mice treated with IFN-α alone or in combination with YM529 was significantly reduced by 84% (P = 0.0330) and 82% (P = 0.0275), respectively, compared with that in control tumors. Moreover, MVD was significantly lower in tumors treated with IFN-α alone (27.2 ± 5.5) or in combination with YM529 (25.7 ± 9.3) than in control tumors (44.8 ± 11.1; P = 0.0252 and P = 0.0275, respectively) and in those of the single-agent YM529-treated group (39.4 ± 8.2; P = 0.0202 and P = 0.0285, respectively; Fig.7).


Combination with third-generation bisphosphonate (YM529) and interferon-alpha can inhibit the progression of established bone renal cell carcinoma.

Kurabayashi A, Inoue K, Fukuhara H, Karashima T, Fukata S, Kawada C, Shuin T, Furihata M - Cancer Sci. (2015)

Micro-vessel density was significantly lower in tumors treated with IFN-α alone or in combination with YM529 than in control tumors (*P = 0.0275, **P = 0.0252) and in tumors of the single-agent YM 529-treatment group (***P = 0.0202, ****P = 0.0285).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4556400&req=5

fig07: Micro-vessel density was significantly lower in tumors treated with IFN-α alone or in combination with YM529 than in control tumors (*P = 0.0275, **P = 0.0252) and in tumors of the single-agent YM 529-treatment group (***P = 0.0202, ****P = 0.0285).
Mentions: mRNA expression of bFGF, VEGF, IL-8, MMP-9, MMP-2, E-cadherin and EGFR was analyzed by ISH (Table3, Fig.6), and MVD was determined by IHC (Fig.7). In RBM1-IT4 cells growing in the tibia of athymic nude mice, bFGF mRNA expression within the tumors of mice treated with IFN-α alone or in combination with YM529 was significantly reduced by 84% (P = 0.0330) and 82% (P = 0.0275), respectively, compared with that in control tumors. Moreover, MVD was significantly lower in tumors treated with IFN-α alone (27.2 ± 5.5) or in combination with YM529 (25.7 ± 9.3) than in control tumors (44.8 ± 11.1; P = 0.0252 and P = 0.0275, respectively) and in those of the single-agent YM529-treated group (39.4 ± 8.2; P = 0.0202 and P = 0.0285, respectively; Fig.7).

Bottom Line: The antiangiogenetic effect by YM529 and/or IFN-α was analyzed using micro-vessel density and in situ mRNA hybridization.Neither YM529 nor IFN-α alone significantly inhibited the growth of established bone metastatic tumors.Their effects are mediated by osteoclast recruitment inhibition and inactivation by YM529 and antiangiogenesis by IFN-α.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Kochi Medical School, Nankoku, Japan.

Show MeSH
Related in: MedlinePlus